Nothing is Better Than Actinium Pharmaceuticals Inc. (ATNM) stock at the moment

Actinium Pharmaceuticals Inc. (AMEX: ATNM) stock jumped 5.45% on Monday to $11.60 against a previous-day closing price of $11.00. With 0.57 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.58 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $11.72 whereas the lowest price it dropped to was $10.73. The 52-week range on ATNM shows that it touched its highest point at $15.12 and its lowest point at $4.41 during that stretch. It currently has a 1-year price target of $31.20. Beta for the stock currently stands at 0.48.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ATNM was up-trending over the past week, with a rise of 14.29%, but this was up by 12.40% over a month. Three-month performance surged to 63.84% while six-month performance rose 139.67%. The stock gained 118.46% in the past year, while it has gained 8.92% so far this year. A look at the trailing 12-month EPS for ATNM yields -1.30 with Next year EPS estimates of -1.59. For the next quarter, that number is -0.35. This implies an EPS growth rate of 34.20% for this year and -22.30% for next year.

Float and Shares Shorts:

At present, 25.16 million ATNM shares are outstanding with a float of 25.00 million shares on hand for trading. On Oct 13, 2022, short shares totaled 0.39 million, which was 1.57% higher than short shares on Sep 14, 2022. In addition to Mr. Sandesh C. Seth M.B.A., M.S., MBA as the firm’s Chairman & CEO, Mr. Steven O’Loughlin BS serves as its CFO & Corp. Sec.


Institutional Ownership:

Through their ownership of 15.50% of ATNM’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 7.25% of ATNM, in contrast to 6.07% held by mutual funds. Shares owned by individuals account for 1.21%. As the largest shareholder in ATNM with 4.16% of the stake, The Vanguard Group, Inc. holds 1,060,054 shares worth 1,060,054. A second-largest stockholder of ATNM, District 2 Capital LP, holds 513,099 shares, controlling over 2.01% of the firm’s shares. BlackRock Fund Advisors is the third largest shareholder in ATNM, holding 247,355 shares or 0.97% stake. With a 2.99% stake in ATNM, the Vanguard Total Stock Market Index is the largest stakeholder. A total of 760,573 shares are owned by the mutual fund manager. The Vanguard Extended Market Index Fu, which owns about 1.22% of ATNM stock, is the second-largest Mutual Fund holder. It holds 310,022 shares valued at 3.3 million. iShares Biotechnology ETF holds 0.82% of the stake in ATNM, owning 208,008 shares worth 2.22 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ATNM since 6 analysts follow the stock currently. There are 6 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With ATNM analysts setting a high price target of $53.00 and a low target of $18.00, the average target price over the next 12 months is $29.12. Based on these targets, ATNM could surge 356.9% to reach the target high and rise by 55.17% to reach the target low. Reaching the average price target will result in a growth of 151.03% from current levels.


EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. ATNM will report FY 2022 earnings on 03/15/2024. Analysts have provided yearly estimates in a range of -$1.02 being high and -$1.38 being low. For ATNM, this leads to a yearly average estimate of -$1.30. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Actinium Pharmaceuticals Inc. surprised analysts by -$0.07 when it reported -$0.38 EPS against a consensus estimate of -$0.30. The surprise factor in the prior quarter was -$0.61. Based on analyst estimates, the high estimate for the next quarter is -$0.09 and the low estimate is -$0.43. The average estimate for the next quarter is thus -$0.35.

Summary of Insider Activity:

Insiders traded ATNM stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 1 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 300,000 while 0 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *